INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53

Genes and Development

Volumn 13, Issue 20, 1999, Pages 2670-2677

  Schmitt, Clemens A ^a   McCurrach, Mila E ^a   De Stanchina, Elisa ^a   Wallace Brodeur, Rachel R ^a   Lowe, Scott W ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

Chemo resistance; INK4a ARF locus; Lymphomagenesis; p53

Indexed keywords

CYCLOPHOSPHAMIDE; MAFOSFAMIDE; PROTEIN P53;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA CONTENT; GENE EXPRESSION REGULATION; GENE LOCUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; STRAIN DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE; ENHANCER ELEMENTS (GENETICS); FEMALE; GENES, MYC; GENES, P16; GENES, P53; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0033569423     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.13.20.2670     Document Type: Article

References (44)

1. Adams, J.M. and S. Cory. 1991. Transgenic models for haemopoietic malignancies. Biochim. Biophys. Acta 1072: 9-31.
2. Adams, J.M., A.W. Harris, C.A. Pinkert, L.M. Corcoran, W.S. Alexander, S. Cory, R.D. Palmiter, and R.L. Brinster. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
3. Bates, S., A.C. Phillips, P.A. Clark, F. Stott, G. Peters, R.L. Ludwig, and K.H. Vousden, 1998. p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125.
4. Beroud, C. and T. Soussi. 1998. p53 gene mutation: Software and database. Nucleic Acids Res. 26: 200-204.
5. Brown, J.M. and B.G. Wouters. 1999. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59: 1391-1399.
6. Bunz, F., P.M. Hwang, C. Torrance, T. Waldman, Y. Zhang, L. Dillehay, J. Williams, C. Lengauer, K.W. Kinzler, and B. Vogelstein. 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104: 263-269.
7. ARF tumor suppressor. Genes & Dev. 12: 2434-2442.
8. Diccianni, M.B., J. Yu, M. Hsiao, S. Mukherjee, L.E. Shao, and A.L. Yu. 1994. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84: 3105-3112.
9. Eischen, C.M., J.D. Weber, M.F. Roussel, C.J. Sherr, and J.L. Cleveland. 1999. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Dev. (this issue).
10. Elrouby, S., A. Thomas, D. Costin, C.R. Rosenberg, M. Potmesil, R. Silber, and E.W. Newcomb. 1993. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452-3459.
11. Fan, S.J., W.S. Eldeiry, I. Bae, J. Freeman, D. Jondle, K. Bhatia, A.J. Fornace, I. Magrath, K.W. Kohn, and P.M. Oconnor. 1994. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830.
12. Giaccia, A.J. and M.B. Kastan. 1998. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes & Dev. 12: 2973-2983.
13. ARF. Cell 91: 555-558.
14. Hermeking, H. and D. Eick. 1994. Mediation of c-myc induced apoptosis by p53. Science 265: 2091-2093.
15. Hsu, B., M.C. Marin, A.K. Elnaggar, L.C. Stephens, S. Brisbay, and T.J. Mcdonnell. 1995. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11: 175-179.
16. Jacks, T., A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, and R.A. Weinberg. 1992. Effects of an Rb mutation in the mouse. Nature 359: 295-300.
17. Jacks, T., L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
18. Jacobs, J.J.L., B. Scheijen, J.-W. Voncken, K. Kieboom, A. Berns, and M. van Lohuizen. (1999). Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc induced apoptosis via Ink4a/ARF. Genes & Dev. (This issue).
19. Jawhs, J.J.L., B. Scheijen, J.-W. Voncken, K. Kreboom, A. Berns, M. van Lohuizen. 1999. Bmi-1 collaborates with cMyc in tumorigenesis by inhibiting c-Myc induced apoptosis via INK4a/ARF. Genes & Dev. (This issue).
20. ARF. Cell 91: 649-659.
21. Kamijo, T., J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. 95: 8292-8297.
22. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
23. Kastan, M.B., Q. Zhan, W.S. el-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A. Fornace Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
24. Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus E1A and accompanies apoptosis. Genes & Dev. 7: 535-545.
25. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74: 954-967.
26. ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126.
27. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
28. Prives, C. 1998. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95: 5-8.
29. Ruas, M. and G. Peters. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378: F115-F177.
30. Schmitt, C.A. and S.W. Lowe. 1999. Apoptosis and therapy. J. Pathol. 187: 127-137.
31. Serrano, M., G.J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK.4. Nature 366: 704-707.
32. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
33. INK4a. Cell 88: 593-602.
34. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 pathway. Genes & Dev. 12: 2984-2991.
35. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014.
36. Strasser, A., A.W. Harris, M.L. Bath, and S. Cory. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
37. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. 96: 6937-6941.
38. Wallace-Brodeur, R.R. and S.W. Lowe. 1999. Clinical implications of p53 mutations. Cell Mol. Life Sci. 55: 64-75.
39. Wattel, E., C. Preudhomme, B. Hecquet, M. Vanrumbeke, B. Quesnel, I. Dervite, P. Morel, and P. Fenaux. 1994. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84: 3148-3157.
40. Weber, J.D., L.J. Taylor, M.F. Roussel, C.J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1: 20-26.
41. Wilson, W.H., J. Teruya-Feldstein, T. Fest, C. Harris, S.M. Steinberg, E.S. Jaffe, and M. Raffeld. 1997. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89: 601-609.
42. Zhang, Y. and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3: 579-591.
43. Zhang, Y., Y. Xiong, and W.G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
44. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.